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THE ACTIVITY OF ANTIOXIDANT
ENZYMES IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE IN COMBINATION
WITH COMORBID OBESITY
Abstract. Background. Chronic obstructive pulmonary disease (COPD)
is one of the most common diseases in the world, whose mortality
continues to increase. The focus of modern medical science and public
health is obesity too, because the number of patients  are steadily
increasing and doubling every three decades. The aim of the study. To
study the dependence of the parameters of antioxidative enzymes in the
blood in patients with chronic obstructive pulmonary disease, depending
on the severity of accompanying obesity. Materials and methods.  The
study involved 19 patients with COPD without obesity, 48 patients with
COPD, combined with obesity grade I, II, III.  We determined the content
of reduced glutathione levels, level of ceruloplasmin in serum, activity of
glutathione peroxidase, glutathione-S-transferase, copper / zinc -
superoxide dismutase, catalase activity in the blood. Results. Found that
in chronic obstructive pulmonary disease observed decrease in reduced
glutathione and activities of copper / zinc superoxide dismutase and
catalase in blood with simultaneous increased ceruloplasmin and
glutathione peroxidase activities and glutathione-S-transferase levels.
These changes are compounded with increasing body mass index and is
most observed in the third degree of accompanying obesity. Conclusions.
In patients with chronic obstructive pulmonary disease, combined with
obesity, there is decompensation of functioning antiradical protection
systems, resulting decrease in reduced glutathione and activities of
superoxide dismutase and catalase levels, the degree of which depends on
the degree of obesity. One form of compensation for breach of antioxidant
defense in chronic obstructive pulmonary disease in conjunction with
obesity is increasing ceruloplasmin and activities of glutathione
peroxidase and glutathione-S-transferase levels, most pronounced in the
third-degree obesity.
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Introduction
Chronic obstructive pulmonary disease (COPD) is
one of the most common diseases in the world, mortality
of which continues to increase [1]. The focus of modern
medical science and public health is obesity too, because
the number of patients  with it is are steadily increasing
and doubling every three decades [2].
Therefore, finding and studying new factors in the
pathogenesis of COPD combined with obesity is one
of the important directions in the development of
effective treatment. We know that one of these
factors is oxidative stress, which is produced as a
result of pathogenic concentration of active oxygen
metabolites, which are controlled by endogenous
antioxidants: catalase (CT), superoxide dismutase
(SOD), glutathione, glutathione peroxidase (GPO),
vitamin E and others. [3].
A lot of researches are devoted to the study of
oxidative stress processes in COPD and obesity, but
their results are rather contradictory. However, the
activity of antioxidant enzymes for COPD combined
with obesity is less explored, depending on the
severity of the latter.
The aim of the study
To study the dependence of the parameters of
antioxidative enzymes in the blood of patients with
chronic obstructive pulmonary disease, depending on
the severity of accompanying obesity.
Materials and methods
The study involved 19 patients with COPD
without obesity (1st group), 18 patients with COPD,
combined with obesity grade I (2nd group), 12
patients with COPD, combined with obesity grade II
(3rd group), 12 patients with COPD, combined with
obesity grade III (4th group) and 18 healthy persons
(5th group). The average age of patients was 53,4 ±
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4,7 years. There was significant difference by age
and sex composition between groups of patients and
healthy individuals. All patients were informed about
the study and expressed their consent.
Body mass index (BMI, BMI - body mass index)
was determined by the formula: BMI = m/h2, where
the m-weight (kg), and h-height (m). Evaluation of
body weight and degree of obesity was conducted by
the WHO classification (1997): Normal weight -
BMI 19-24,9 kg/m2, overweight - BMI 25-29,9 kg/
m2, and obesity degree - BMI 30-34 9 kg/m2, second
degree - BMI 35-39,9 kg/m2, third degree - BMI e”
40 kg/m2. Diagnosis and stage of COPD according
to the established order of the Ministry of Health of
Ukraine ¹ 128 of 19.03.2007.
We determined the content of reduced glutathione
(RG) levels by titration method of O.V.Travina
(1955) as modified I.F. Meshchyshen, I.V. Petrova
(1983) modification. The level of ceruloplasmin (CP)
in serum was determined by the method of Revina
(V.H.Kolb, 1976). The activity of glutathione
peroxidase (GP) (EC 1.11.1.9) was examined
according to I.F. Meshchyshen (1982) method, the
activity of glutathione-S-transferase (GT) (EC
2.5.1.18) – by I.F. Meshchyshen (1987), the activity
of copper / zinc - superoxide dismutase (SOD) (EC
1.15.1.11) – according to R.Fried (1975), catalase
activity (KT) (EC 1.11.1.6) – by M.A. Koroliuk et al.
method (1988). Activation of enzymes was
calculated per 1 g of hemoglobin (Hb).
Statistical analysis of the results was made on a
personal computer using the software package
licensed «Microsoft Excel 2010» (Microsoft) and
«Statistica ® 6.0» (StatSoft Inc., USA).
Discussion
Analysis of the data presented in the table shows that
in COPD there is a decrease in reduced glutathione
levels by 19,3% (p<0,05), activities of copper / zinc
superoxide dismutase and catalase (16.7% and 15, 4%,
respectively, p<0.05) with a simultaneous increase in
serum ceruloplasmin at 23,8% (p<0,05) and activities
of glutathione peroxidase and glutathione-S-transferase
levels (by 31.2% and 30, 4%, respectively, p<0,05) as
compared with those in healthy individuals.
In the presence of accompanying obesity in patients
with COPD changes in these parameters were more
significant (Table). In particular, for the first-degree
obesity RG content and SOD activity and CT decreased
as compared with in healthy individuals at 29,5%,
31,4%, 23,1% (p<0,05), for II-degree – by 44,3%,
42,2%, 33,5% (p<0,001), for third-degree – 58%,
53.6%, 48.4%, respectively (p<0,001). The level and
activity of CP, GPO and GT significantly (p<0,05)
increased respectively by 39.0%, 60.3%, 52.8% (in the
second group of patients), at 58.5%, 75.8 %, 68.1% (in
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the third group of patients), at 77.7%, 94.1%, 120.6%
(in the fourth group of patients).
However, when comparing the data in the first and
second groups only indicators of SOD activity (p <0,05)
differed significantly in the first and third groups – RG
content indicators, activities of SOD, KT, GPO, GT (p
<0,05); in the first and fourth groups - RG content
indicators, securities activities of SOD, KT, GPO, GT
(p <0,05), in the second and fourth groups - indicators
of RG content, SOD activity and GT (p <0,05).
Differences between parameters in patients with
COPD, and combined with the first degree of obesity
and in patients with COPD combined with second
degree obesity were unreliable (p>0,05).
Thus, in COPD there is decompensation of
functioning antiradical protection systems, the resulting
of which is a decrease in reduced glutathione content
and SOD activity and CP levels. One form of the
compensation mechanisms for violations of antioxidant
defense is improving  ceruloplasmin activities in GPO
and GT levels. These changes are intensified with
increasing body mass index and are the most observed
in the third degree of accompanying obesity.
Obviously, a stable oxidative stress in patients with
COPD is associated with an increased influence of
exogenous oxidants (smoke), increased production of
endogenous oxidants due to inflammation / recurrent
infection / oxygen therapy, suboptimal sufficiently
powerful antioxidant protection and greater generation
of oxidants due to a chain reaction. It is known that
oxidative stress “conducts” inflammatory response /
malfunction of the immune system that causes damage
to the lungs. Thus, we can substantiate the oxidant /
antioxidant hypothesis development and progression of
COPD, including against a background of obesity.
Moreover, this hypothesis provides a rationale to
explain the pathogenic mechanisms of COPD and
choosing the right approach to therapeutic strategy for
management of these patients [3].
Taking into consideration the obtained the findings,
it should be noted that antioxidants can become a
universal part of the medical appointments against a
background standard therapeutic regimens of the
patients with COPD in combination with obesity.
Conclusions
1. In patients with chronic obstructive pulmonary
disease, combined with obesity, there is decompen-
sation of functioning antiradical protection systems, that
is shown by the decrease in reduced glutathione and
activities of superoxide dismutase and catalase levels,
the degree of which depends on the degree of obesity.
2. One of the compensation mechanisms of
antioxidant defense disorder in chronic obstructive
pulmonary disease in combination with obesity is an
increase of ceruloplasmin level and activities of
glutathione peroxidase and glutathione-S-transferase
levels in the blood, the most pronounced in the third-
degree obesity.
Prospects for further research
We will continue research as to effectiveness of
drugs use with antioxidant action in chronic obstructive
pulmonary disease in combination with obesity - one of
the main components of the metabolic syndrome.
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ÀÊÒÈÂÍ²ÑÒÜ ÀÍÒÈÎÊÑÈÄÀÍÒÍÈÕ ÔÅÐÌÅÍÒ²Â
ÏÐÈ ÕÐÎÍ²×ÍÎÌÓ ÎÁÑÒÐÓÊÒÈÂÍÎÌÓ
ÇÀÕÂÎÐÞÂÀÍÍ² ËÅÃÅÍÜ Ó ÏÎªÄÍÀÍÍ² Ç
ÎÆÈÐ²ÍÍßÌ
Ã.ß.Ñòóïíèöüêà, Î.².Ôåä³â
Ðåçþìå. Ïðè îáñòåæåíí³ 61 õâîðîãî òà 18 ïðàêòè÷íî
çäîðîâèõ îñ³á âñòàíîâëåíî, ùî ïðè õðîí³÷íîìó îáñòðóêòèâ-
íîìó çàõâîðþâàíí³ ëåãåíü ñïîñòåð³ãàºòüñÿ äåêîìïåíñàö³ÿ
ôóíêö³îíóâàííÿ çàõèñíèõ ïðîòèðàäèêàëüíèõ ñèñòåì, ùî
ïðîÿâëÿºòüñÿ çìåíøåííÿì âì³ñòó â³äíîâëåíîãî ãëóòàò³îíó òà
àêòèâíîñòåé ì³äü/öèíê-ñóïåðîêñèääèñìóòàçè òà êàòàëàçè â
êðîâ³. Îäíèì ³ç ìåõàí³çì³â êîìïåíñàö³¿ ïîðóøåíü àíòèîêñè-
äàíòíîãî çàõèñòó º ï³äâèùåííÿ ð³âíÿ öåðóëîïëàçì³íó òà àê-
òèâíîñòåé ãëóòàò³îíïåðîêñèäàçè òà ãëóòàò³îí-S-òðàíñôåðà-
çè â êðîâ³. Çàçíà÷åí³ çì³íè ïîãëèáëþþòüñÿ ³ç çá³ëüøåííÿì
³íäåêñó ìàñè ò³ëà ³ º íàéá³ëüø âèðàæåíèìè çà ²²² ñòóïåíÿ
ñóïðîâ³äíîãî îæèð³ííÿ.
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À.ß.Ñòóïíèöêàÿ, À.È. Ôåäèâ
Ðåçþìå. Ïðè îáñëåäîâàíèè 61 áîëüíîãî è 18 ïðàêòè÷åñ-
êè çäîðîâûõ ëèö óñòàíîâëåíî, ÷òî ïðè õðîíè÷åñêîì îáñòðóê-
òèâíîì çàáîëåâàíèè ëåãêèõ íàáëþäàåòñÿ äåêîìïåíñàöèÿ
ôóíêöèîíèðîâàíèÿ çàùèòíûõ àíòèðàäèêàëüíûõ ñèñòåì, ÷òî
ïðîÿâëÿåòñÿ óìåíüøåíèåì ñîäåðæàíèÿ âîññòàíîâëåííîãî
ãëóòàòèîíà è àêòèâíîñòåé ìåäü/öèíê-ñóïåðîêñèääèñìóòàçû
è êàòàëàçû â êðîâè. Îäíèì èç ìåõàíèçìîâ êîìïåíñàöèè íà-
ðóøåíèé àíòèîêñèäàíòíîé çàùèòû ÿâëÿåòñÿ ïîâûøåíèå
óðîâíÿ öåðóëëîïëàçìèíà è àêòèâíîñòåé ãëóòàòèîíïåðîêñè-
äàçû òà ãëóòàòèîíòðàíñôåðàçû â êðîâû. Óêàçàííûå èçìåíå-
íèÿ óãëóáëÿþòñÿ ïî ìåðå ïîâûøåíèÿ èíäåêñà ìàññû òåëà è
ÿâëÿþòñÿ íàèáîëåå âûðàæåííûìè ïðè ²²² ñòåïåíè ñîïóòñòâó-
þùåãî îæèðåíèÿ.
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